Response to : “Special editorial: When prescribing Janus kinase inhibitors for dermatologic conditions, be mindful of the Food and Drug Administration's September 1, 2021, data safety communication”. / Rick, Jonathan W.; Lio, Peter; Hsiao, Jennifer L. et al.In: Journal of the American Academy of Dermatology, Vol. 87, No. 1, 07.2022, p. e33-e34.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Response to
T2 - “Special editorial: When prescribing Janus kinase inhibitors for dermatologic conditions, be mindful of the Food and Drug Administration's September 1, 2021, data safety communication”
AU - Rick, Jonathan W.
AU - Lio, Peter
AU - Hsiao, Jennifer L.
AU - Shi, Vivian Y.
N1 - Funding Information: Dr Shi is on the board of directors for the Hidradenitis Suppurativa Foundation, is a stock shareholder of Learn Health, and has served as an advisory board member, investigator, speaker, and/or received research funding from Sanofi Genzyme, Regeneron, AbbVie, Eli Lilly, Novartis, Sun Pharma, LEO Pharma, Pfizer, Incyte, Boehringer Ingelheim, Aristea Therapeutics, Menlo Therapeutics, Dermira, Burt’s Bees, Galderma, Kiniksa, UCB, TARGET PharmaSolutions, Altus Lab/CQuell, MYOR, Polyfins Technology, GpSkin, Skin Actives Scientific and the National Eczema Association. Dr Hsiao is on the board of directors for the Hidradenitis Suppurativa Foundation and is a consultant for Novartis and speaker for AbbVie. Dr Lio reports research grants/funding from the National Eczema Association, Regeneron/Sanofi Genzyme, and AbbVie; is on the speaker’s bureau for Regeneron/Sanofi Genzyme, Pfizer, and L’Oreal; and reports consulting/advisory board work for UCB, Dermavant, Regeneron/Sanofi Genzyme, Dermira, Pfizer, LEO Pharmaceuticals, AbbVie, Kiniksa, Eli Lilly, Micreos (stock options), La Roche Posay/L’Oreal, Pierre Fabre, Johnson & Johnson, Unilever, Menlo Therapeutics, Theraplex, IntraDerm, Exeltis, AOBiome, Realm Therapeutics, Franklin Bioscience/Altus Labs (stock options), Verrica, TopMD, Arbonne, Amyris, Bodewell, and Burt’s Bees. In addition, Dr Lio has a patent pending for a Theraplex product, with royalties paid, and is a board member and Scientific Advisory Committee member of the National Eczema Association. Dr Rick has no conflicts of interest to declare.
PY - 2022/7
Y1 - 2022/7
UR - http://www.scopus.com/inward/record.url?scp=85131956958&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2022.03.019
DO - 10.1016/j.jaad.2022.03.019
M3 - Letter
C2 - 35307489
AN - SCOPUS:85131956958
VL - 87
SP - e33-e34
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
SN - 0190-9622
IS - 1